382 related articles for article (PubMed ID: 20226717)
1. Directing systemic oncolytic viral delivery to tumors via carrier cells.
Nakashima H; Kaur B; Chiocca EA
Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
[TBL] [Abstract][Full Text] [Related]
2. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
3. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells.
Nguyen TL; Wilson MG; Hiscott J
Cytokine Growth Factor Rev; 2010; 21(2-3):153-9. PubMed ID: 20395162
[TBL] [Abstract][Full Text] [Related]
8. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
Power AT; Bell JC
Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
10. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions.
Kim J; Hall RR; Lesniak MS; Ahmed AU
Viruses; 2015 Nov; 7(12):6200-17. PubMed ID: 26633462
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
12. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
[TBL] [Abstract][Full Text] [Related]
13. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.
Power AT; Bell JC
Mol Ther; 2007 Apr; 15(4):660-5. PubMed ID: 17264852
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenoviruses - selective retargeting to tumor cells.
Mathis JM; Stoff-Khalili MA; Curiel DT
Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration.
Na Y; Nam JP; Hong J; Oh E; Shin HC; Kim HS; Kim SW; Yun CO
J Control Release; 2019 Jul; 305():75-88. PubMed ID: 31071373
[TBL] [Abstract][Full Text] [Related]
16. The utility of cells as vehicles for oncolytic virus therapies.
Russell SJ; Peng KW
Curr Opin Mol Ther; 2008 Aug; 10(4):380-6. PubMed ID: 18683103
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
[TBL] [Abstract][Full Text] [Related]
18. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.
Guo ZS; Thorne SH; Bartlett DL
Biochim Biophys Acta; 2008 Apr; 1785(2):217-31. PubMed ID: 18328829
[TBL] [Abstract][Full Text] [Related]
20. Achieving systemic delivery of oncolytic viruses.
Hill C; Carlisle R
Expert Opin Drug Deliv; 2019 Jun; 16(6):607-620. PubMed ID: 31144549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]